To learn more about our world-renowned researchers, please select from the list below.
Dr. Nicole Beauchemin has been a pioneer in the field of carcinoembryonic antigen (CEA) and has developed a robust project on defining this gene family, characterizing the CEACAM1 gene and proteins and investigating the functions of this protein in colon cancer initiation, development and metastatic progression using cellular and mouse models.
Dr. Duchaine’s group focuses on the RNA- interference (RNAi) pathways, such as the diverse endogenous RNAi pathways and microRNA-mediated silencing. They examine the impact of these gene silencing mechanisms on the regulation of gene networks and their roles in cancer.
The Giguère lab studies the role of nuclear receptors in development, physiology and diseases, especially in hormone-dependent cancers.
Dr. Huang’s group uses functional genomic tools to study cancer-relevant pathways and to guide cancer therapy. They aim to identify mechanisms of drug resistance and to uncover cancer dependencies that can be exploited therapeutically.
Dr. McCaffrey’s lab addresses fundamental questions in cell biology to understand mechanisms of breast cancer initiation and progression. His lab utilizes animal models, 3D organoids, and patient-derived tissue to interrogate dynamic behaviors between normal or cancer cells and their microenvironment. A goal of this research is to understand how cell and tissue organization influence the growth and invasive properties in cancer, to improve predictive, preventative, and therapeutic options.
Dr Nepveu's group investigates how alterations in DNA repair and DNA damage responses contribute to the initiation and progression of cancer. The group is looking at how certain cancer cells become dependent on the base excision repair pathway, and how efficient base excision repair can enable cancer cells to resist radiotherapy and chemotherapy. One goal is to identify "druggable" biochemical activities that are essential to cancer cells, but dispensable to normal cells, in order to develop novel therapeutics.
Dr. Pause’s group studies cancer-relevant signalling pathways involved in energy metabolism and cell surface receptor trafficking
Dr. Quail’s lab studies the role of the tumor microenvironment during cancer initiation and progression. Their primary interest is the myeloid compartment in tumor immunology.
Dr. Sonenberg’s research focuses on the molecular basis of the control of protein synthesis in eukaryotic cells and its importance in cancer and neurological diseases. Our research has identified various mRNA translation factors involved in the control of protein synthesis along with their integration with several key signalling pathways, we believe targeting these pathways should facilitate the design of novel therapeutic.
In order to understand and find cures for human diseases, Dr Tremblay's lab focuses on protein tyrosine phosphatases (PTPases), which play an essential role in many biological and pathological processes. The lab is aiming to develop new treatments for a broad range of human diseases such as diabetes, obesity, spinal cord injury and infectious diseases as well as diverse cancers.
Dr. Ian Watson's research focuses on understanding how mutated genes identified in next-generation sequencing studies promote cutaneous melanoma disease progression by modulating the response to targeted therapies and immune checkpoint inhibitors. To address this challenge, his lab utilizes an inter-disciplinary approach combining unbiased molecular characterization of melanoma tumors, rapid development of preclinical models using genome-editing technology, and bioinformatics tools.
Xiang Jiao Yang
Dr. Yang has been investigating the intimate link of epigenetic regulation to developmental disorders (such as syndromic intellectual disability) and cancer, with a key interest in how different stem cells (like neural and hematopoietic stem cell) develop and are then maintained.
Dr. Bouchard’s lab is interested in the molecular networks regulating processes such as cell lineage specification, epithelialization and epithelial integrity, tubular extension, apoptotic morphogenesis and proliferation control.
Dr. Chen’s lab focuses on engineering intelligent biomaterials for drug delivery, with the ultimate goal towards precision medicine. They are also interested in understanding and exploiting the interactions between biomaterials and biological systems for therapeutic applications.
The research programs of the Gallouzi lab focus on delineating the role of RNA binding proteins (RBPs) in the negative effects of cancer on muscle integrity and function. Dr. Gallouzi's group is also studying how aging alters the function of RBPs to promote age-related diseases.
Dr. Gros uses genetic analysis in mutant mouse models and in human patients cohorts to identify the molecular pathways and proteins required for protection against infections and whose sustained activation leads to chronic inflammation..
The central theme of the Kazak lab is the molecular control of mammalian energy metabolism and its influence on physiology. The lab uses genetic and biochemical approaches in purified organelles, cultured cells and genetically engineered mice to investigate the control of thermogenic pathways in brown adipocytes that support energy expenditure.
Dr. Muller's lab develops genetically engineered mouse models (GEMMs) to investigate mammary tumourigenesis, tumour progression and metastasis. Through combining GEMMs with molecular and cellular techniques, bioinformatic approaches and analysis of clinical samples, they identify critical signaling pathways and potential therapeutic targets in breast cancer, focusing on aggressive luminal tumours and those driven by the oncogene ErbB2/HER2.
Dr. Morag Park’s lab focuses on: 1) The molecular and cellular biology of the receptor tyrosine kinase and proto-oncogene MET, its functions and regulation in normal cells and malignant cells; 2) The composition, organization and functional roles of the tumour microenvironment, particularly in triple negative breast cancer (TNBC). By integrating cutting edge cellular, transgenic and patient-derived models with unique biobanks of breast cancer patient samples, they uncover key mechanisms involved in tumourigenesis, tumour progression and drug resistance.
Dr. Pelletier applies chemical biology and genetic approaches to dissect and target vulnerabilities in the translation initiation pathway. Insight gained from these studies will help better understand the regulation of tumor intrinsic and extrinsic survival processes.
The Siegel lab is focused on delineating mechanisms that control cancer cells' ability to metastasize to different organs and tissues in the body. Our research investigates how cancer cells interact with the distinct microenvironments to form metastases in sites like the bone, lungs, liver or brain. We work to identify functionally important and clinically validated mediators of the metastatic process that can be targeted through the generation of novel therapeutic agents.
Dr. Teodoro’s research program aims to identify the molecular pathways that limit tumour growth and to delineate the mechanisms by which they become subverted in cancer.
Dr Walsh's lab focuses on using translational genetics and immunogenomics to develop personalized medicine strategies.
Dr. Yamanaka’s group studies the mechanisms regulating epithelial morphogenesis in development and cancer. Using mouse models and in vitro 3D culture, they investigate early events of ovarian cancer and peritoneal metastasis.
Dr. George Zogopoulos’ research focuses on the genetics and oncogenomics of pancreaticobiliary cancers.